HKEX
1177
SBP GROUP
HKD 5.1900
0.1900 (+3.8000%)
Last updated: 10 Jul 2026 4:08:35 PM
DelayedDelayed at least 15 minutes
Last updated: 10 Jul 2026 4:08:35 PM (Singapore Time)
HKEX1177
SBP GROUP
DelayedDelayed at least 15 minutes
HKD 5.1900
+3.8000%
+ HKD 0.1900
Open
HKD 5.0500
Prev. Close
HKD 5.0000
Bid
HKD 5.1800
Bid Volume
811,000
Ask
HKD 5.1900
Ask Volume
639,000
Total Volume
177,337,052
4.8700
Day's Range
5.3500
4.1900
52 Weeks Range
9.1200
SHOW ALL KEY STATISTICS
1177 Chart
Delayed
Chart data is delayed at least 15 minutes.
Created with Highcharts 9.3.2Chart context menu13. Apr20. Apr27. Apr4. May11. May18. May25. May1. Jun8. Jun15. Jun22. Jun29. Jun6. Jul44.555.566.5FSM Global
Stock Information
Market Cap
HKD 92.25 billion
Share Outstanding
17.77 billion
30 Days Average Volume
114.60 million
Product Currency
HKD
Valuations
Earning Per Share
CNH 0.130
Price-to-Earnings Ratio (PE)
33.397
Historical Avg. PE Ratio
23.341
Price-to-Book Ratio (PB)
2.512
Price-to-Sales Ratio (PS)
2.459
Price/Earnings-to-Growth Ratio
-
Selected Financial Data
Free Cash Flow
CNH 7.59 billion
Debt-to-Equity Ratio
0.249
Current Ratio
1.368
Quick Ratio
1.223
Return On Equity (%)
7.48
Return On Assets (%)
3.31
Dividend Info
Hist. Annual Dividend
0.050
Forward Div. Yield (%)
2.000
Pay-out Ratio (%)
63.280
Last Div. Ex Date
24 Jun 2026
Next Div. Ex Date
-
Financial InformationMORE
Created with Highcharts 9.3.2Chart context menuRevenueNet Income20252024202320222021010.00B20.00B30.00B40.00B
(CNH)
2025 YOY Change
2024 YOY Change
2023 YOY Change
2022 YOY Change
2021 YOY Change
Revenue
31.83B
10.28%
28.87B
10.18%
26.20B
-8.97%
28.78B
7.14%
26.86B
13.59%
Operating Income
6.90B
8.93%
6.33B
9.49%
5.79B
-4.15%
6.04B
38.98%
4.34B
0.91%
Net Income
2.34B
-33.04%
3.50B
50.08%
2.33B
-8.32%
2.54B
-82.59%
14.61B
427.17%
About SBP GROUP
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
Sector
Healthcare
Industry Classification
Biotechnology
Product Type
MAIN
Sales
CNH 31.83 billion
Market Cap
HKD 92.25 billion
Net Income
CNH 2.34 billion
Share Outstanding
17.77 billion
Fiscal Year End
31 Dec 2026
52 Weeks Range
HKD 4.1900 - HKD 9.1200
Employees
21,435
30 Days Average Volume
114.60 million
Payment Method
Included under CashYes
Included under CPFIS OANo
Included under CPFIS SANo
Included under SRSNo
Upcoming Exchange HolidaysMORE
Hong Kong
30Sep
National Day
18Oct
The Day following Chung Yeung Festival
23Dec
Eve of Christmas (Half-Day Trading)
24Dec
Christmas Day
30Dec
Eve of New Year (Half-Day Trading)
Tools
newCalculatorIcon
Stock Calculator
newCalculatorIcon
Stock Returns
newScreenerSelectorIcon
Stock Screener
newCalculatorIcon
Intrinsic Value Calculator
newGainerIcon
Top Gainer Loser
Related ArticlesMORE
STOCK & ETF IDEAS
2 defensive dividend stocks investors should consider
By The Motley Fool Hong Kong
04 Nov 2019 | 7767 views